Insys Therapeutics Inc (INSY) : 12 West Capital Management Lp added new position in Insys Therapeutics Inc during the most recent quarter end. The investment management firm now holds 623,791 shares of Insys Therapeutics Inc which is valued at $11,459,041 , the company said in a statement filed on Aug 15, 2016 with the SEC.Insys Therapeutics Inc makes up approximately 1.47% of 12 West Capital Management Lp’s portfolio.
Other Hedge Funds, Including , D. E. Shaw added INSY to its portfolio by purchasing 103,441 company shares during the most recent quarter which is valued at $1,900,211.Parametric Portfolio Associates boosted its stake in INSY in the latest quarter, The investment management firm added 2,328 additional shares and now holds a total of 15,197 shares of Insys Therapeutics Inc which is valued at $279,169. Raymond James Financial Services Advisors sold out all of its stake in INSY during the most recent quarter. The investment firm sold 60,554 shares of INSY which is valued $1,112,377.Alliancebernstein boosted its stake in INSY in the latest quarter, The investment management firm added 2,150 additional shares and now holds a total of 61,120 shares of Insys Therapeutics Inc which is valued at $1,122,774. Healthinvest Partners Ab added INSY to its portfolio by purchasing 788,175 company shares during the most recent quarter which is valued at $12,484,692. Insys Therapeutics Inc makes up approx 5.48% of Healthinvest Partners Ab’s portfolio.
Insys Therapeutics Inc opened for trading at $14.43 and hit $14.655 on the upside on Thursday, eventually ending the session at $14.36, with a gain of 0.63% or 0.09 points. The heightened volatility saw the trading volume jump to 3,71,622 shares. Company has a market cap of $1,028 M.
On the company’s financial health, Insys Therapeutics Inc reported $0.13 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $0.07. The company had revenue of $67.10 million for the quarter, compared to analysts expectations of $66.94 million. The company’s revenue was down -13.6 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.21 EPS.
Insys Therapeutics Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company has two marketed products: Subsys a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and Dronabinol SG Capsule a generic equivalent to Marinol (dronabinol) an approved second-line treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS. The Companys lead product candidate is Dronabinol oral solution an orally administered liquid formulation of dronabinol. Dronabinol oral solution has demonstrated more rapidly detectable blood levels and a more reliable absorption profile than Marinol in its clinical studies.